Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shaping A Shkreli Bill: Voucher Abuse Solution May Stumble On FDA Effects

Executive Summary

House bill that would require new clinical studies from sponsor for tropical disease priority review vouchers met with industry concerns about limiting the US agency's flexibility.

You may also be interested in...



'Repeal And Replace' Going Relatively Well For Pharma So Far

US White House game plan for repealing and replacing the Affordable Care Act includes a proposal for faster generic drug approvals but no direct government price controls.

Bill To Speed ANDA Approvals Gets Cool Reception From Industry, US FDA

At House hearing, FDA and AAM highlight logistical challenges of legislation's six-month ANDA review goal and potential to put GDUFA II agreement at risk.

Rare Disease OPEN-ing In PDUFA Possible For Drug Repurposing Advocates

OPEN ACT would provide additional six months of exclusivity when existing drugs are approved for rare diseases; congressional debate over the measure could get bogged down in drug pricing issues.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS120168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel